Overall, this study provides promising preclinical data on the potential of APN-LNP as a novel therapy for obesity-related bone disorders, offering both metabolic and osteogenic benefits. The gene discussed is ANPEP; the disease is obesity due to melanocortin 4 receptor deficiency.